Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.

Identifieur interne : 001618 ( Main/Exploration ); précédent : 001617; suivant : 001619

The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.

Auteurs : Xinqun Li [États-Unis] ; Zhen Fan

Source :

RBID : pubmed:20634405

Descripteurs français

English descriptors

Abstract

Autophagy is a regulated catabolic process triggered in cells deprived of nutrients or growth factors that govern nutrient uptake. Here, we report that autophagy is induced by cetuximab, a therapeutic antibody that blocks epidermal growth factor receptor function. Cancer cell treatment with cetuximab triggered autophagosome formation, conversion of microtubule-associated protein 1 light chain 3 from its cytoplasmic to membrane-associated form, and increased acidic vesicular organelle formation. Autophagy occurred when cetuximab inhibited the class I phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin pathway, but not when it inhibited only the mitogen-activated protein/extracellular signal-regulated kinase kinase/Erk pathway, and it was accompanied by decreased levels of hypoxia inducible factor-1 alpha (HIF-1alpha) and Bcl-2. Stable overexpression of a HIF-1alpha mutant prevented cetuximab-induced autophagy and decrease in Bcl-2 levels. Knockdown of autophagy regulator beclin 1 or cell treatment with autophagy inhibitor 3-methyladenine, a class III PI3K (hVps34) inhibitor, also inhibited cetuximab-induced autophagy. Furthermore, knockdown of beclin 1 or Atg7 or treatment with the lysosome inhibitor chloroquine sensitized cancer cells to cetuximab-induced apoptosis. Mechanistic analysis argued that cetuximab acted by promoting an association between beclin 1 and hVps34, which was inhibited by overexpression of Bcl-2. Our findings suggest that the autophagy protects cancer cells from the proapoptotic effects of cetuximab.

DOI: 10.1158/0008-5472.CAN-10-0157
PubMed: 20634405


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.</title>
<author>
<name sortKey="Li, Xinqun" sort="Li, Xinqun" uniqKey="Li X" first="Xinqun" last="Li">Xinqun Li</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030</wicri:regionArea>
<wicri:noRegion>Texas 77030</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Fan, Zhen" sort="Fan, Zhen" uniqKey="Fan Z" first="Zhen" last="Fan">Zhen Fan</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20634405</idno>
<idno type="pmid">20634405</idno>
<idno type="doi">10.1158/0008-5472.CAN-10-0157</idno>
<idno type="wicri:Area/PubMed/Corpus">000395</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000395</idno>
<idno type="wicri:Area/PubMed/Curation">000395</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000395</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000381</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000381</idno>
<idno type="wicri:Area/Ncbi/Merge">000138</idno>
<idno type="wicri:Area/Ncbi/Curation">000138</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000138</idno>
<idno type="wicri:Area/Main/Merge">001621</idno>
<idno type="wicri:Area/Main/Curation">001618</idno>
<idno type="wicri:Area/Main/Exploration">001618</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.</title>
<author>
<name sortKey="Li, Xinqun" sort="Li, Xinqun" uniqKey="Li X" first="Xinqun" last="Li">Xinqun Li</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030</wicri:regionArea>
<wicri:noRegion>Texas 77030</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Fan, Zhen" sort="Fan, Zhen" uniqKey="Fan Z" first="Zhen" last="Fan">Zhen Fan</name>
</author>
</analytic>
<series>
<title level="j">Cancer research</title>
<idno type="eISSN">1538-7445</idno>
<imprint>
<date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adenocarcinoma (drug therapy)</term>
<term>Adenocarcinoma (pathology)</term>
<term>Antibodies, Monoclonal (pharmacology)</term>
<term>Antibodies, Monoclonal, Humanized</term>
<term>Apoptosis Regulatory Proteins (metabolism)</term>
<term>Autophagy (drug effects)</term>
<term>Beclin-1</term>
<term>Carcinoma, Non-Small-Cell Lung (drug therapy)</term>
<term>Carcinoma, Non-Small-Cell Lung (pathology)</term>
<term>Carcinoma, Squamous Cell (drug therapy)</term>
<term>Carcinoma, Squamous Cell (pathology)</term>
<term>Cetuximab</term>
<term>Colorectal Neoplasms (drug therapy)</term>
<term>Colorectal Neoplasms (pathology)</term>
<term>Down-Regulation (drug effects)</term>
<term>ErbB Receptors (antagonists & inhibitors)</term>
<term>Female</term>
<term>Humans</term>
<term>Hypoxia-Inducible Factor 1, alpha Subunit (biosynthesis)</term>
<term>Hypoxia-Inducible Factor 1, alpha Subunit (genetics)</term>
<term>Intracellular Signaling Peptides and Proteins (metabolism)</term>
<term>Lung Neoplasms (drug therapy)</term>
<term>Lung Neoplasms (pathology)</term>
<term>MAP Kinase Kinase Kinases (antagonists & inhibitors)</term>
<term>MAP Kinase Kinase Kinases (metabolism)</term>
<term>Membrane Proteins (metabolism)</term>
<term>Neoplasms (drug therapy)</term>
<term>Neoplasms (metabolism)</term>
<term>Neoplasms (pathology)</term>
<term>Phosphatidylinositol 3-Kinases (metabolism)</term>
<term>Phosphoinositide-3 Kinase Inhibitors</term>
<term>Protein-Serine-Threonine Kinases (metabolism)</term>
<term>Proto-Oncogene Proteins c-akt (antagonists & inhibitors)</term>
<term>Proto-Oncogene Proteins c-akt (metabolism)</term>
<term>Proto-Oncogene Proteins c-bcl-2 (biosynthesis)</term>
<term>Proto-Oncogene Proteins c-bcl-2 (genetics)</term>
<term>TOR Serine-Threonine Kinases</term>
<term>Vesicular Transport Proteins (metabolism)</term>
<term>Vulvar Neoplasms (drug therapy)</term>
<term>Vulvar Neoplasms (pathology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adénocarcinome (anatomopathologie)</term>
<term>Adénocarcinome (traitement médicamenteux)</term>
<term>Anticorps monoclonaux (pharmacologie)</term>
<term>Anticorps monoclonaux humanisés</term>
<term>Autophagie ()</term>
<term>Bécline-1</term>
<term>Carcinome pulmonaire non à petites cellules (anatomopathologie)</term>
<term>Carcinome pulmonaire non à petites cellules (traitement médicamenteux)</term>
<term>Carcinome épidermoïde (anatomopathologie)</term>
<term>Carcinome épidermoïde (traitement médicamenteux)</term>
<term>Cétuximab</term>
<term>Femelle</term>
<term>Humains</term>
<term>MAP Kinase Kinase Kinases (antagonistes et inhibiteurs)</term>
<term>MAP Kinase Kinase Kinases (métabolisme)</term>
<term>Phosphatidylinositol 3-kinases (métabolisme)</term>
<term>Protein-Serine-Threonine Kinases (métabolisme)</term>
<term>Protéines du transport vésiculaire (métabolisme)</term>
<term>Protéines et peptides de signalisation intracellulaire (métabolisme)</term>
<term>Protéines membranaires (métabolisme)</term>
<term>Protéines proto-oncogènes c-akt (antagonistes et inhibiteurs)</term>
<term>Protéines proto-oncogènes c-akt (métabolisme)</term>
<term>Protéines proto-oncogènes c-bcl-2 (biosynthèse)</term>
<term>Protéines proto-oncogènes c-bcl-2 (génétique)</term>
<term>Protéines régulatrices de l'apoptose (métabolisme)</term>
<term>Récepteurs ErbB (antagonistes et inhibiteurs)</term>
<term>Régulation négative ()</term>
<term>Sous-unité alpha du facteur-1 induit par l'hypoxie (biosynthèse)</term>
<term>Sous-unité alpha du facteur-1 induit par l'hypoxie (génétique)</term>
<term>Sérine-thréonine kinases TOR</term>
<term>Tumeurs (anatomopathologie)</term>
<term>Tumeurs (métabolisme)</term>
<term>Tumeurs (traitement médicamenteux)</term>
<term>Tumeurs colorectales (anatomopathologie)</term>
<term>Tumeurs colorectales (traitement médicamenteux)</term>
<term>Tumeurs de la vulve (anatomopathologie)</term>
<term>Tumeurs de la vulve (traitement médicamenteux)</term>
<term>Tumeurs du poumon (anatomopathologie)</term>
<term>Tumeurs du poumon (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en">
<term>ErbB Receptors</term>
<term>MAP Kinase Kinase Kinases</term>
<term>Proto-Oncogene Proteins c-akt</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en">
<term>Hypoxia-Inducible Factor 1, alpha Subunit</term>
<term>Proto-Oncogene Proteins c-bcl-2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>Hypoxia-Inducible Factor 1, alpha Subunit</term>
<term>Proto-Oncogene Proteins c-bcl-2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Apoptosis Regulatory Proteins</term>
<term>Intracellular Signaling Peptides and Proteins</term>
<term>MAP Kinase Kinase Kinases</term>
<term>Membrane Proteins</term>
<term>Protein-Serine-Threonine Kinases</term>
<term>Proto-Oncogene Proteins c-akt</term>
<term>Vesicular Transport Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Antibodies, Monoclonal</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Adénocarcinome</term>
<term>Carcinome pulmonaire non à petites cellules</term>
<term>Carcinome épidermoïde</term>
<term>Tumeurs</term>
<term>Tumeurs colorectales</term>
<term>Tumeurs de la vulve</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr">
<term>MAP Kinase Kinase Kinases</term>
<term>Protéines proto-oncogènes c-akt</term>
<term>Récepteurs ErbB</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr">
<term>Protéines proto-oncogènes c-bcl-2</term>
<term>Sous-unité alpha du facteur-1 induit par l'hypoxie</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Autophagy</term>
<term>Down-Regulation</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Adenocarcinoma</term>
<term>Carcinoma, Non-Small-Cell Lung</term>
<term>Carcinoma, Squamous Cell</term>
<term>Colorectal Neoplasms</term>
<term>Lung Neoplasms</term>
<term>Neoplasms</term>
<term>Vulvar Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr">
<term>Protéines proto-oncogènes c-bcl-2</term>
<term>Sous-unité alpha du facteur-1 induit par l'hypoxie</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Neoplasms</term>
<term>Phosphatidylinositol 3-Kinases</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>MAP Kinase Kinase Kinases</term>
<term>Phosphatidylinositol 3-kinases</term>
<term>Protein-Serine-Threonine Kinases</term>
<term>Protéines du transport vésiculaire</term>
<term>Protéines et peptides de signalisation intracellulaire</term>
<term>Protéines membranaires</term>
<term>Protéines proto-oncogènes c-akt</term>
<term>Protéines régulatrices de l'apoptose</term>
<term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Adenocarcinoma</term>
<term>Carcinoma, Non-Small-Cell Lung</term>
<term>Carcinoma, Squamous Cell</term>
<term>Colorectal Neoplasms</term>
<term>Lung Neoplasms</term>
<term>Neoplasms</term>
<term>Vulvar Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Anticorps monoclonaux</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Adénocarcinome</term>
<term>Carcinome pulmonaire non à petites cellules</term>
<term>Carcinome épidermoïde</term>
<term>Tumeurs</term>
<term>Tumeurs colorectales</term>
<term>Tumeurs de la vulve</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en">
<term>Antibodies, Monoclonal, Humanized</term>
<term>Beclin-1</term>
<term>Cetuximab</term>
<term>Female</term>
<term>Humans</term>
<term>Phosphoinositide-3 Kinase Inhibitors</term>
<term>TOR Serine-Threonine Kinases</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Anticorps monoclonaux humanisés</term>
<term>Autophagie</term>
<term>Bécline-1</term>
<term>Cétuximab</term>
<term>Femelle</term>
<term>Humains</term>
<term>Régulation négative</term>
<term>Sérine-thréonine kinases TOR</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Autophagy is a regulated catabolic process triggered in cells deprived of nutrients or growth factors that govern nutrient uptake. Here, we report that autophagy is induced by cetuximab, a therapeutic antibody that blocks epidermal growth factor receptor function. Cancer cell treatment with cetuximab triggered autophagosome formation, conversion of microtubule-associated protein 1 light chain 3 from its cytoplasmic to membrane-associated form, and increased acidic vesicular organelle formation. Autophagy occurred when cetuximab inhibited the class I phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin pathway, but not when it inhibited only the mitogen-activated protein/extracellular signal-regulated kinase kinase/Erk pathway, and it was accompanied by decreased levels of hypoxia inducible factor-1 alpha (HIF-1alpha) and Bcl-2. Stable overexpression of a HIF-1alpha mutant prevented cetuximab-induced autophagy and decrease in Bcl-2 levels. Knockdown of autophagy regulator beclin 1 or cell treatment with autophagy inhibitor 3-methyladenine, a class III PI3K (hVps34) inhibitor, also inhibited cetuximab-induced autophagy. Furthermore, knockdown of beclin 1 or Atg7 or treatment with the lysosome inhibitor chloroquine sensitized cancer cells to cetuximab-induced apoptosis. Mechanistic analysis argued that cetuximab acted by promoting an association between beclin 1 and hVps34, which was inhibited by overexpression of Bcl-2. Our findings suggest that the autophagy protects cancer cells from the proapoptotic effects of cetuximab.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Fan, Zhen" sort="Fan, Zhen" uniqKey="Fan Z" first="Zhen" last="Fan">Zhen Fan</name>
</noCountry>
<country name="États-Unis">
<noRegion>
<name sortKey="Li, Xinqun" sort="Li, Xinqun" uniqKey="Li X" first="Xinqun" last="Li">Xinqun Li</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001618 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001618 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:20634405
   |texte=   The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:20634405" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021